Latest revenue
$20.8M
as of 2026-03-31
Latest net income
$-3.4M
as of 2026-03-31
Net margin
-16.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $25.2M
- Enterprise value
- $25.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $7.50
- 52-wk low
- $0.28
- Beta
- —
- Shares out
- 4.5M
5-year trend
What this company does
Overview Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Our products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations (“CROs”). With operations in the United States, Europe and China, we sell through a combination of direct and distribution channels to…
AI summary unavailable — showing raw filing excerpt
Generated from HBIO's filing dated 2026-03-13
Key risks
The following factors should be reviewed carefully, in conjunction with the other information contained in this Annual Report on Form 10-K. As previously discussed, our actual results could differ materially from the information included in our forward-looking statements. Our business faces a variety of risks. These risks include those described below and may include additional risks and uncertainties not presently known to us or that we currently deem immaterial. If any of the events or circumstances described in the following risk factors occur or develop, our business operations, financial performance and financial condition could be materially and adversely affected, and the trading…
AI summary unavailable — showing raw filing excerpt
Generated from HBIO's filing dated 2026-03-13
Profitability
Gross margin
57.7%
0.9%Operating margin
-56.1%
750.7%Net margin
-65.5%
397.1%Return on equity
-412.8%
2331.9%Return on assets
-70.8%
622.9%Leverage
Debt / equity
4.83×
558.9%Long-term debt / equity
2.61×
Debt / assets
82.8%
95.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $20.8M | -4.7% | $-3.4M | +93.2% | -16.5% |
Q4 2025 2025-12-31 | $23.7M | -3.3% | $-2.8M | -15916.7% | -12.0% |
Q3 2025 2025-09-30 | $20.6M | -6.3% | $-1.2M | +74.4% | -6.0% |
Q2 2025 2025-06-30 | $20.4M | -11.5% | $-2.3M | +22.0% | -11.2% |
Q1 2025 2025-03-31 | $21.8M | -11.2% | $-50.3M | -972.4% | -231.2% |
Q4 2024 2024-12-31 | $24.6M | — | $18.0K | — | 0.1% |
Q3 2024 2024-09-30 | $22.0M | -13.4% | $-4.8M | -287.6% | -21.9% |
Q2 2024 2024-06-30 | $23.1M | -19.7% | $-2.9M | -717.6% | -12.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Laboratory Analytical Instruments · SIC 3826
Your notes
Keep private notes on HBIO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$202.4K
Insider selling
$0
Net activity
+$202.4K
Distinct insiders
4
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns HBIO
Institutional value
$0
Total shares held
30
Distinct holders
1
-63 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Financial Connections Group, Inc. | 30 | $0 | -270 (-90.0%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once HBIO's latest filing finishes processing.